Adeona Pharmaceuticals, Inc. (AEN), a development-stage, specialty pharmaceutical company, has dedicated its efforts to developing proprietary, late-stage drug candidates designed to treat autoimmune and central nervous system (CNS) diseases. The company’s strategy is to exclusively in-license proprietary, clinical-stage drug candidates that have proven clinical efficacy for the treatment medical diseases that are as of yet unattended to. For further information, visit the Company’s web site at www.adeonapharma.com.
- 17 years ago
QualityStocks
Adeona Pharmaceuticals, Inc. AEN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Nightfood Holdings Inc. (NGTF) Positioning to Lead Future of Hospitality
Nightfood Holdings (OTCQB: NGTF) is rapidly expanding its footprint in the hospitality and hotel automation sectors…
-
QualityStocksNewsBreaks – Nicola Mining Inc. (TSXV: NIM) (FSE: HLIA) (OTCQB: HUSIF) Coverage Initiated with Outperform Rating, Target Set at C$0.70 / US$0.50
Nicola Mining (TSXV: NIM) (FSE: HLIA) (OTCQB: HUSIF) a junior exploration company with near-term cash…
-
QualityStocksNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Signs LOI to Launch PLAY LEAP Digital Fan Platform
Brera Holdings (NASDAQ: BREA), a global sports investment group, has signed a letter of intent…